Levofloxacin Use in TB Bronchiectasis with Possible Hospital-Acquired Pneumonia

Introduction to Levofloxacin Use

The Centers for Disease Control and Prevention recommends that levofloxacin should not be used as empiric monotherapy in patients with TB bronchiectasis due to the risk of masking tuberculosis, delaying appropriate multi-drug TB therapy, and promoting fluoroquinolone resistance in M. tuberculosis 1

The presence of TB bronchiectasis creates an absolute contraindication to empiric fluoroquinolone use unless the patient is already receiving concurrent standard four-drug TB therapy, as stated by the World Health Organization 1
Fluoroquinolones have activity against Mycobacterium tuberculosis and can produce misleading initial clinical improvement in TB patients, delaying diagnosis and appropriate treatment, according to the Centers for Disease Control and Prevention 1

For suspected hospital-acquired pneumonia in a patient with TB bronchiectasis, the Infectious Diseases Society of America recommends using a non-fluoroquinolone regimen, such as IV beta-lactam (ceftriaxone 2g IV q24h, cefotaxime, or ampicillin-sulbactam) PLUS azithromycin 1, 5
If Pseudomonas risk factors are present, the Infectious Diseases Society of America recommends using an antipseudomonal beta-lactam (piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, or meropenem 1g IV q8h) PLUS aminoglycoside (amikacin 15-20 mg/kg IV q24h or tobramycin 5-7 mg/kg IV q24h) 5

For rifampicin-susceptible, isoniazid-resistant TB, the European Respiratory Society recommends rifampicin + ethambutol + pyrazinamide + levofloxacin 500-1000 mg daily for 6 months 4
For MDR/RR-TB, the World Health Organization recommends levofloxacin (Group A drug) + bedaquiline + linezolid + at least one Group B agent 4

The Centers for Disease Control and Prevention warns that fluoroquinolones should never be used empirically when TB is in the differential diagnosis without concurrent four-drug TB therapy 1
Cross-resistance exists among all fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin), so resistance to one affects all, according to the Infectious Diseases Society of America 2